SE459471B - Liposomal aerosolkomposition samt foerfarande och foerpackning foer framstaellning daerav - Google Patents
Liposomal aerosolkomposition samt foerfarande och foerpackning foer framstaellning daeravInfo
- Publication number
- SE459471B SE459471B SE8404118A SE8404118A SE459471B SE 459471 B SE459471 B SE 459471B SE 8404118 A SE8404118 A SE 8404118A SE 8404118 A SE8404118 A SE 8404118A SE 459471 B SE459471 B SE 459471B
- Authority
- SE
- Sweden
- Prior art keywords
- component
- chamber
- components
- mixing chamber
- aerosol
- Prior art date
Links
- 239000000443 aerosol Substances 0.000 title claims description 78
- 239000000203 mixture Substances 0.000 title claims description 58
- 238000000034 method Methods 0.000 title claims description 55
- 238000004806 packaging method and process Methods 0.000 title claims description 7
- 238000002360 preparation method Methods 0.000 title description 15
- 239000002502 liposome Substances 0.000 claims description 64
- 238000002156 mixing Methods 0.000 claims description 58
- 239000000463 material Substances 0.000 claims description 52
- 239000011149 active material Substances 0.000 claims description 46
- 239000007921 spray Substances 0.000 claims description 43
- 239000003380 propellant Substances 0.000 claims description 39
- 150000002632 lipids Chemical class 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 150000001875 compounds Chemical class 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 12
- 150000003904 phospholipids Chemical group 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 7
- 239000000446 fuel Substances 0.000 claims description 7
- 239000003981 vehicle Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 229940124630 bronchodilator Drugs 0.000 claims description 4
- 239000000470 constituent Substances 0.000 claims description 4
- 230000001088 anti-asthma Effects 0.000 claims description 3
- 239000000924 antiasthmatic agent Substances 0.000 claims description 3
- 238000009826 distribution Methods 0.000 claims description 3
- 239000012042 active reagent Substances 0.000 claims description 2
- 239000003263 anabolic agent Substances 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 239000003433 contraceptive agent Substances 0.000 claims description 2
- 230000007935 neutral effect Effects 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 229940124558 contraceptive agent Drugs 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 70
- 235000019441 ethanol Nutrition 0.000 description 31
- 239000000243 solution Substances 0.000 description 31
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 30
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 20
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 19
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 19
- 239000008344 egg yolk phospholipid Substances 0.000 description 19
- 239000011521 glass Substances 0.000 description 19
- 229960000912 stanozolol Drugs 0.000 description 17
- LKAJKIOFIWVMDJ-IYRCEVNGSA-N Stanazolol Chemical compound C([C@@H]1CC[C@H]2[C@@H]3CC[C@@]([C@]3(CC[C@@H]2[C@@]1(C)C1)C)(O)C)C2=C1C=NN2 LKAJKIOFIWVMDJ-IYRCEVNGSA-N 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 235000012000 cholesterol Nutrition 0.000 description 15
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 14
- 238000010276 construction Methods 0.000 description 11
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 10
- 239000000787 lecithin Substances 0.000 description 10
- 229940067606 lecithin Drugs 0.000 description 10
- 235000010445 lecithin Nutrition 0.000 description 10
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 9
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000008367 deionised water Substances 0.000 description 8
- 229910021641 deionized water Inorganic materials 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 229960000585 bitolterol mesylate Drugs 0.000 description 7
- HODFCFXCOMKRCG-UHFFFAOYSA-N bitolterol mesylate Chemical compound CS([O-])(=O)=O.C1=CC(C)=CC=C1C(=O)OC1=CC=C(C(O)C[NH2+]C(C)(C)C)C=C1OC(=O)C1=CC=C(C)C=C1 HODFCFXCOMKRCG-UHFFFAOYSA-N 0.000 description 7
- RNPXCFINMKSQPQ-UHFFFAOYSA-N dicetyl hydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(=O)OCCCCCCCCCCCCCCCC RNPXCFINMKSQPQ-UHFFFAOYSA-N 0.000 description 7
- 229940093541 dicetylphosphate Drugs 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 229960000890 hydrocortisone Drugs 0.000 description 7
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 7
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 6
- APUPEJJSWDHEBO-UHFFFAOYSA-P ammonium molybdate Chemical compound [NH4+].[NH4+].[O-][Mo]([O-])(=O)=O APUPEJJSWDHEBO-UHFFFAOYSA-P 0.000 description 6
- 239000011609 ammonium molybdate Substances 0.000 description 6
- 229940010552 ammonium molybdate Drugs 0.000 description 6
- 235000018660 ammonium molybdate Nutrition 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 238000010348 incorporation Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 5
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 4
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 4
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- 229960002052 salbutamol Drugs 0.000 description 4
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 229960002537 betamethasone Drugs 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 229960000265 cromoglicic acid Drugs 0.000 description 3
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 238000004062 sedimentation Methods 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- -1 vaccines Substances 0.000 description 3
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960004620 bitolterol Drugs 0.000 description 2
- FZGVEKPRDOIXJY-UHFFFAOYSA-N bitolterol Chemical compound C1=CC(C)=CC=C1C(=O)OC1=CC=C(C(O)CNC(C)(C)C)C=C1OC(=O)C1=CC=C(C)C=C1 FZGVEKPRDOIXJY-UHFFFAOYSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- MEFBJEMVZONFCJ-UHFFFAOYSA-N molybdate Chemical compound [O-][Mo]([O-])(=O)=O MEFBJEMVZONFCJ-UHFFFAOYSA-N 0.000 description 2
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 235000011008 sodium phosphates Nutrition 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229940124091 Keratolytic Drugs 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000004479 aerosol dispenser Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 229960004311 betamethasone valerate Drugs 0.000 description 1
- SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- KILNVBDSWZSGLL-UHFFFAOYSA-N colfosceril palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-UHFFFAOYSA-N 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229940047135 glycate Drugs 0.000 description 1
- 239000000118 hair dye Substances 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- ZUVCYFMOHFTGDM-UHFFFAOYSA-N hexadecyl dihydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(O)=O ZUVCYFMOHFTGDM-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002664 inhalation therapy Methods 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 1
- 239000003580 lung surfactant Substances 0.000 description 1
- 229940066294 lung surfactant Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 231100001228 moderately toxic Toxicity 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- QVGLHVDBDYLFON-UHFFFAOYSA-M sodium;1,3-dimethylpurin-7-ide-2,6-dione Chemical compound [Na+].O=C1N(C)C(=O)N(C)C2=C1[N-]C=N2 QVGLHVDBDYLFON-UHFFFAOYSA-M 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Otolaryngology (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB838322178A GB8322178D0 (en) | 1983-08-17 | 1983-08-17 | Preparing aerosol compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| SE8404118D0 SE8404118D0 (sv) | 1984-08-16 |
| SE8404118L SE8404118L (sv) | 1985-02-18 |
| SE459471B true SE459471B (sv) | 1989-07-10 |
Family
ID=10547457
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE8404118A SE459471B (sv) | 1983-08-17 | 1984-08-16 | Liposomal aerosolkomposition samt foerfarande och foerpackning foer framstaellning daerav |
Country Status (22)
| Country | Link |
|---|---|
| JP (1) | JPS6089414A (enEXAMPLES) |
| KR (1) | KR850001689A (enEXAMPLES) |
| AT (1) | AT389993B (enEXAMPLES) |
| AU (1) | AU569314B2 (enEXAMPLES) |
| BE (1) | BE900375A (enEXAMPLES) |
| CH (1) | CH667384B (enEXAMPLES) |
| DE (1) | DE3430385A1 (enEXAMPLES) |
| DK (1) | DK163479C (enEXAMPLES) |
| ES (1) | ES8506445A1 (enEXAMPLES) |
| FI (1) | FI85214C (enEXAMPLES) |
| FR (1) | FR2550706B1 (enEXAMPLES) |
| GB (2) | GB8322178D0 (enEXAMPLES) |
| GR (1) | GR80127B (enEXAMPLES) |
| IE (1) | IE57537B1 (enEXAMPLES) |
| IL (1) | IL72590A (enEXAMPLES) |
| IT (1) | IT1175612B (enEXAMPLES) |
| LU (1) | LU85512A1 (enEXAMPLES) |
| NL (1) | NL8402514A (enEXAMPLES) |
| NZ (1) | NZ209112A (enEXAMPLES) |
| PT (1) | PT79104B (enEXAMPLES) |
| SE (1) | SE459471B (enEXAMPLES) |
| ZA (1) | ZA846064B (enEXAMPLES) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3585967D1 (de) * | 1984-03-08 | 1992-06-11 | Phares Pharma Holland | Liposombildende zusammensetzung. |
| GB8423436D0 (en) * | 1984-09-17 | 1984-10-24 | Riker Laboratories Inc | Preparation of liposomes |
| CA1260393A (en) * | 1984-10-16 | 1989-09-26 | Lajos Tarcsay | Liposomes of synthetic lipids |
| GB8502892D0 (en) * | 1985-02-05 | 1985-03-06 | Sterwin Ag | Aerosol composition |
| US5192528A (en) | 1985-05-22 | 1993-03-09 | Liposome Technology, Inc. | Corticosteroid inhalation treatment method |
| AU587472B2 (en) * | 1985-05-22 | 1989-08-17 | Liposome Technology, Inc. | Liposome inhalation method and system |
| US5340587A (en) * | 1985-05-22 | 1994-08-23 | Liposome Technology, Inc. | Liposome/bronchodilator method & System |
| GB8522964D0 (en) * | 1985-09-17 | 1985-10-23 | Biocompatibles Ltd | Aerosol |
| EP0221821A3 (en) * | 1985-11-01 | 1988-01-27 | Centre National De La Recherche Scientifique (Cnrs) | New aerosol composition for in vivo imaging and therapy |
| IE63869B1 (en) * | 1986-11-06 | 1995-06-14 | Res Dev Foundation | Aerosols containing liposomes and method for their preparation |
| US4897256A (en) * | 1986-11-25 | 1990-01-30 | Abbott Laboratories | LHRH analog formulations |
| US4828837A (en) * | 1987-03-30 | 1989-05-09 | Liposome Technology, Inc. | Non-crystalline minoxidil composition, its production and application |
| US5030442A (en) * | 1987-03-30 | 1991-07-09 | Liposome Technology, Inc. | Non-crystalline minoxidil composition |
| JP2581920B2 (ja) * | 1987-05-18 | 1997-02-19 | 有限会社野々川商事 | 化粧料 |
| FR2638639A1 (fr) * | 1988-11-08 | 1990-05-11 | Parincos Parfumerie Cosmet Int | Composition et procede d'obtention de liposomes oligolamellaires en vue d'une application en cosmetologie et dermatologie topique |
| JPH03193714A (ja) * | 1989-12-25 | 1991-08-23 | Kobayashi Kose Co Ltd | エアゾール型化粧料 |
| DE4203306A1 (de) * | 1992-02-06 | 1993-08-12 | Ig Spruehtechnik Gmbh | Asthma oder pulmonal-aerosolzubereitungen mit lecithin |
| EP0616801B1 (de) * | 1993-03-24 | 1998-05-27 | Novartis AG | Verfahren zur Herstellung einer Liposomendispersion im Hochdruckbereich |
| CA2163860A1 (en) * | 1993-06-30 | 1995-01-12 | Chung C. Hsu | Method for preparing liposomes |
| GB9409763D0 (en) * | 1994-05-16 | 1994-07-06 | Phares Pharma Holland | Liposome forming compositions |
| ES2111488B1 (es) * | 1996-01-17 | 1998-11-01 | Lucas Meyer S A | Utilizacion de composiciones proliposomas en la tintura, blanqueo y suavizado de la industrial textil y procedimiento para la preparacion de banos de tintura a partir de dichas composiciones proliposomas. |
| WO1998055104A1 (fr) * | 1997-06-06 | 1998-12-10 | Shionogi & Co., Ltd. | Perfectionnement d'un systeme d'administration de medicament |
| EP1013268A1 (en) * | 1998-06-30 | 2000-06-28 | Rohto Pharmaceutical Co., Ltd. | Compositions containing liposomes and/or emulsions and process for the preparation thereof |
| EP1839648A3 (en) * | 1998-11-12 | 2007-11-21 | Transave, Inc. | An inhalation system |
| WO2000027359A1 (en) * | 1998-11-12 | 2000-05-18 | Pilkiewicz Frank G | An inhalation system |
| US7718189B2 (en) | 2002-10-29 | 2010-05-18 | Transave, Inc. | Sustained release of antiinfectives |
| US7879351B2 (en) | 2002-10-29 | 2011-02-01 | Transave, Inc. | High delivery rates for lipid based drug formulations, and methods of treatment thereof |
| HUE025491T2 (en) | 2002-10-29 | 2016-04-28 | Insmed Inc | Delayed release of anti-infective agents |
| AU2006307460A1 (en) * | 2005-10-26 | 2007-05-03 | New York University | A method for preparing liposomes and uses thereof |
| CA2896083A1 (en) | 2005-12-08 | 2007-06-14 | Insmed Incorporated | Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof |
| CA2649025A1 (en) * | 2006-04-11 | 2007-10-18 | Wingturf Co., Ltd. | Production method of liposome dispersion and production equipment thereof |
| WO2008137717A1 (en) | 2007-05-04 | 2008-11-13 | Transave, Inc. | Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods and uses thereof |
| US9333214B2 (en) | 2007-05-07 | 2016-05-10 | Insmed Incorporated | Method for treating pulmonary disorders with liposomal amikacin formulations |
| US9114081B2 (en) | 2007-05-07 | 2015-08-25 | Insmed Incorporated | Methods of treating pulmonary disorders with liposomal amikacin formulations |
| US9119783B2 (en) | 2007-05-07 | 2015-09-01 | Insmed Incorporated | Method of treating pulmonary disorders with liposomal amikacin formulations |
| JP5572636B2 (ja) * | 2008-12-29 | 2014-08-13 | ペトロヴィッチ グレベンニコヴ，イヴゲニー | リポソーム医薬の製造方法及びリポソーム製造装置 |
| RU2470624C1 (ru) * | 2011-08-25 | 2012-12-27 | Евгений Петрович Гребенников | Устройство для получения липосомальных препаратов |
| EP4005576B1 (en) | 2012-05-21 | 2023-12-13 | Insmed Incorporated | Systems for treating pulmonary infections |
| MX2015006681A (es) | 2012-11-29 | 2016-04-06 | Insmed Inc | Formulaciones de vancomicina estabilizadas. |
| US20150224077A1 (en) | 2014-02-10 | 2015-08-13 | Patara Pharma, LLC | Methods for the Treatment of Systemic Disorders Treatable with Mast Cell Stabilizers, including Mast Cell Related Disorders |
| WO2015120392A1 (en) | 2014-02-10 | 2015-08-13 | Patara Pharma, LLC | Mast cell stabilizers for lung disease treatment |
| KR102489036B1 (ko) | 2014-05-15 | 2023-01-13 | 인스메드 인코포레이티드 | 폐의 비-결핵성 마이코박테리아 감염을 치료하기 위한 방법 |
| US10238625B2 (en) | 2015-08-07 | 2019-03-26 | Respivant Sciences Gmbh | Methods for the treatment of mast cell related disorders with mast cell stabilizers |
| US10265296B2 (en) | 2015-08-07 | 2019-04-23 | Respivant Sciences Gmbh | Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders |
| CN110139646A (zh) | 2016-08-31 | 2019-08-16 | 瑞思皮万特科学有限责任公司 | 用于治疗由特发性肺纤维化引起的慢性咳嗽的色甘酸组合物 |
| JP2019531308A (ja) | 2016-10-07 | 2019-10-31 | レシュピファント サイエンシス ゲゼルシャフト ミット ベシュレンクター ハフトゥングＲｅｓｐｉｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ | 肺線維症の治療のためのクロモリン組成物 |
| JP7008975B2 (ja) * | 2017-08-31 | 2022-01-25 | クラシエホームプロダクツ株式会社 | 皮膚化粧料 |
| WO2019191627A1 (en) | 2018-03-30 | 2019-10-03 | Insmed Incorporated | Methods for continuous manufacture of liposomal drug products |
| US12121073B2 (en) * | 2020-07-17 | 2024-10-22 | Kt&G Corporation | Pressurization device for aerosol generating article and aerosol generating system including the same |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB780885A (en) * | 1955-05-03 | 1957-08-07 | Innoxa England Ltd | Foundation cream |
| GB993702A (en) * | 1961-11-10 | 1965-06-02 | Takeda Chemical Industries Ltd | An aerosol dispersing agent |
| DE1277210B (de) * | 1965-09-24 | 1968-09-12 | Revlon | Selbsttreibende Gemische |
| US3326416A (en) * | 1966-01-14 | 1967-06-20 | Du Pont | Apparatus for codispensing a plurality of liquids |
| US3325056A (en) * | 1966-02-23 | 1967-06-13 | Du Pont | Apparatus for codispensing a plurality of liquids |
| US3338479A (en) * | 1966-04-04 | 1967-08-29 | Leonard L Marraffino | Mixing head with secondary fluid adapted for connection with discharge means of primary fluid container |
| GB1287470A (en) * | 1968-11-25 | 1972-08-31 | Gillette Co | Pressurised dispensing package |
| US3594476A (en) * | 1969-05-12 | 1971-07-20 | Massachusetts Inst Technology | Submicron aqueous aerosols containing lecithin |
| NL7012832A (enEXAMPLES) * | 1970-08-29 | 1972-03-02 | ||
| US3637114A (en) * | 1970-09-03 | 1972-01-25 | Philip Meshberg | Device for codispensing two materials |
| GB1372721A (en) * | 1971-01-16 | 1974-11-06 | Wilkinson Sword Ltd | Containers of antiseptics for the treatment of burns and scalds |
| DE2115926C3 (de) * | 1971-04-01 | 1978-05-03 | C.H. Boehringer Sohn, 6507 Ingelheim | 1 -(4-Hydroxy-3-dimethylaminosuIfamidophenyI)-2-aminoäthanderivate, Verfahren zu ihrer Herstellung und diese enthaltende Mittel |
| US3997467A (en) * | 1971-11-26 | 1976-12-14 | Pharmacia Aktiebolag | Foam forming composition |
| DE2346730C3 (de) * | 1973-09-17 | 1980-10-16 | Carl Heyer Gmbh, Inhalationstechnik, 5427 Bad Ems | Einrichtung zur Aerosolbehandlung von Menschen, Tieren, Gegenständen, Stoffen u.dgl. in einem Behandlungsraum |
| LU70720A1 (enEXAMPLES) * | 1974-08-12 | 1976-08-19 | ||
| US4073412A (en) * | 1976-06-03 | 1978-02-14 | Blue Cross Laboratories, Inc. | Emulsified cookware lubricant having freeze-thaw stability |
| GB1575343A (en) * | 1977-05-10 | 1980-09-17 | Ici Ltd | Method for preparing liposome compositions containing biologically active compounds |
| GB2001334B (en) * | 1977-07-19 | 1982-03-03 | Fisons Ltd | Pressurised aerosol formulation |
| FR2416008A1 (fr) * | 1978-02-02 | 1979-08-31 | Oreal | Lyophilisats de liposomes |
| CH646390A5 (de) * | 1980-05-12 | 1984-11-30 | Polyfill Ag | Druckdose. |
| DE3207289A1 (de) * | 1982-03-01 | 1983-09-15 | Perfect-Valois Ventil GmbH, 4600 Dortmund | Abgabeventil fuer aerosoldosen |
| EP0100964A3 (de) * | 1982-07-31 | 1984-06-13 | Reifenrath, Rainer, Dr. | Pharmazeutisches Erzeugnis zur Behandlung und Prophylaxe von Infektionen sowie von Husten und obstruktiven Atemwegserkrankungen sowie Verfahren zu seiner Herstellung |
| FR2543018B1 (fr) * | 1983-03-22 | 1985-07-26 | Oreal | Procede de preparation de vesicules lipidiques par vaporisation de solvants |
| CH664943A5 (de) * | 1983-08-16 | 1988-04-15 | Sterwin Ag | Zweikomponentenpackung. |
-
1983
- 1983-08-17 GB GB838322178A patent/GB8322178D0/en active Pending
-
1984
- 1984-08-03 NZ NZ209112A patent/NZ209112A/xx unknown
- 1984-08-06 ZA ZA846064A patent/ZA846064B/xx unknown
- 1984-08-06 IL IL72590A patent/IL72590A/xx unknown
- 1984-08-10 AU AU31786/84A patent/AU569314B2/en not_active Ceased
- 1984-08-14 ES ES535163A patent/ES8506445A1/es not_active Expired
- 1984-08-15 DE DE19843430385 patent/DE3430385A1/de not_active Withdrawn
- 1984-08-15 FI FI843223A patent/FI85214C/fi not_active IP Right Cessation
- 1984-08-16 DK DK392884A patent/DK163479C/da not_active IP Right Cessation
- 1984-08-16 JP JP59170982A patent/JPS6089414A/ja active Pending
- 1984-08-16 GB GB08420850A patent/GB2145107B/en not_active Expired
- 1984-08-16 IE IE2121/84A patent/IE57537B1/en not_active IP Right Cessation
- 1984-08-16 NL NL8402514A patent/NL8402514A/nl not_active Application Discontinuation
- 1984-08-16 GR GR80127A patent/GR80127B/el unknown
- 1984-08-16 SE SE8404118A patent/SE459471B/sv not_active IP Right Cessation
- 1984-08-16 CH CH395884A patent/CH667384B/xx not_active IP Right Cessation
- 1984-08-16 AT AT0263684A patent/AT389993B/de not_active IP Right Cessation
- 1984-08-16 KR KR1019840004923A patent/KR850001689A/ko not_active Withdrawn
- 1984-08-17 IT IT22357/84A patent/IT1175612B/it active
- 1984-08-17 FR FR8412930A patent/FR2550706B1/fr not_active Expired
- 1984-08-17 LU LU85512A patent/LU85512A1/fr unknown
- 1984-08-17 BE BE0/213504A patent/BE900375A/fr not_active IP Right Cessation
- 1984-08-17 PT PT79104A patent/PT79104B/pt not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SE459471B (sv) | Liposomal aerosolkomposition samt foerfarande och foerpackning foer framstaellning daerav | |
| Gungor et al. | Nanocarriers mediated topical drug delivery for psoriasis treatment | |
| US5653996A (en) | Method for preparing liposomes | |
| AU587472B2 (en) | Liposome inhalation method and system | |
| JP3676976B2 (ja) | 多胞状リポソームへの薬剤封入量の調節 | |
| TW497974B (en) | High dose liposomal aerosol formulations | |
| EP0190926B1 (en) | A method for the preparation of liposomes, a pack for use therein and a composition for use in preparing a liposomal material | |
| IE63869B1 (en) | Aerosols containing liposomes and method for their preparation | |
| Tomizawa et al. | Uptake of phosphatidylserine liposomes by rat Peyer's patches following intraluminal administration | |
| HU198835B (en) | Process for producing pharmaceutical compositions forming liposomes | |
| JPH05507090A (ja) | 直接噴霧乾燥された薬剤／脂質粉末組成物 | |
| US5654000A (en) | Pharmaceutical compositions for transmucosal delivery of peptides | |
| US11712407B2 (en) | Hybrid-type multi-lamellar nanostructure of epidermal growth factor and liposome and method for manufacturing same | |
| EP1385478B1 (de) | Verfahren zum aufbringen eines wirkstoffs auf ein substrat, zusammensetzungen für das verfahren, behälter enthaltend eine zusammensetzung und verwendung der zusammensetzungen | |
| Kumar et al. | Formulation & Evaluation of Flubriprofen Drug Loaded Liposomes | |
| NO171707B (no) | Fremgangsmaate og forpakning for fremstilling av aerosoler | |
| JP3202705B2 (ja) | 医療用のリポソームおよび薬物含有リポソームのエアゾールの小粒子 | |
| Venkatesh | A review on: Liposomes | |
| JP3202704B2 (ja) | 医療用のリポソームおよび薬物含有リポソームのエアゾールの小粒子 | |
| Reddy et al. | International Journal of Indigenous Herbs and Drugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |
Ref document number: 8404118-5 Effective date: 19940310 Format of ref document f/p: F |